Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Background Concerns regarding statin-related neurocognitive disorders have emerged in recent years. However, previous studies have reported inconsistent results. We evaluated the association between statins and neurocognitive disorders using the FDA Adverse Event Reporting System (FAERS).